A compound found in sunless tanning spray may help to heal wounds following surgery, according to new results published by plastic surgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City and biomedical engineers at Cornell University in Ithaca, N.Y., where the novel compound was developed.
Results published today in the Proceedings of the National Academy of Sciences show that a sticky gel composed of polyethylene glycol and a polycarbonate of dihydroxyacetone (MPEG-pDHA) may help to seal wounds created by surgery.
Procedures to remove cancerous breast tissue, for example, often leave a hollow space that fills with seroma fluid that must typically be drained by a temporary implanted drain. "This is an unpleasant side effect of surgery that is often unavoidable," explains Dr. Jason Spector, co-author of the study and plastic surgeon at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
The gel could potentially be used in all different reconstructive surgeries to prevent seroma formation. "The new substance would act to glue together the hole left behind to prevent seroma buildup," says Dr. Spector.
DHA is a compound that sticks to compounds in biological tissues, called amines. The sticky properties of DHA are what allows sunless tanner to adhere to the skin without being wiped off. However, it is biodegradable and water soluble as well, which means that the compound does not stay tacked onto the body's tissues forever. Currently used "bio-glues" are made from animal products and take a long time to degrade in the body -- both factors that raise the risk of infection.
"DHA is a compound that is naturally produced in the body," explains Dr. David Putnam, the study's senior author and a biomedical engineer from Cornell University's Department of Biomedical Engineering and School of Chemical and Biomolecular Engineering. "The glue is broken down, or metabolized, and then safely removed by the body."
Dr. Putnam's lab and his collaborators work to create safe, synthetic compounds from chemicals found in nature. DHA is an intermediary compound produced during the metabolism of glucose, a sugar used by the body for fuel.
To create the new compound, MPEG-pDHA, Dr. Putnam and his lab first bound the single molecule monomer of DHA, which is highly reactive, to a protecting group molecule, making it stable enough to manipulate. This allowed the engineers to bind the monomers together to form a polymer, or chain of molecules, along with MPEG. Doing so allows the polymer gel to be injected through a syringe.
"Making a polymer from DHA has eluded chemical engineers for about 20 years," says Dr. Putnam.
Now in gel form, the compound has the ability to stick tissues together, preventing the pocket from filling with seroma fluid, like an internal Band-Aid, explains Dr. Putnam. The researchers found that the gel prevented or significantly lowered seroma formation or fluid buildup in rats that had breast tissue removed.
"The next step would be to test the gel on larger animals and then in clinical trials in human surgical cases," says Dr. Spector.
Previous results, published by Drs. Putnam and Spector, in the August 2009 issue of the Journal of Biomedical Materials Research, showed that the gel also prevented bleeding in a rat liver.
"This is another aspect of the compound that would be greatly beneficial if proven to be applicable in humans," says Dr. Spector. "The gel could speed the healing and decrease bleeding within the body."
This research was supported in part from a National Science Foundation CAREER Award, a grant from the Morgan Tissue Engineering Fund, an Early Career Award from the Wallace H. Coulter Foundation, and the New York State Center for Advanced Technology.
Co-authors of the study include Dr. Peter Zawaneh from Cornell University, Dr. Sunil Singh and Dr. Peter Henderson from Weill Cornell, and Dr. Robert Padera from the Department of Pathology at Brigham and Women's Hospital.
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
NewYork-Presbyterian Hospital/Weill Cornell Medical Center, located in New York City, is one of the leading academic medical centers in the world, comprising the teaching hospital NewYork-Presbyterian and Weill Cornell Medical College, the medical school of Cornell University. NewYork-Presbyterian/Weill Cornell provides state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine, and is committed to excellence in patient care, education, research and community service. Weill Cornell physician-scientists have been responsible for many medical advances -- including the development of the Pap test for cervical cancer; the synthesis of penicillin; the first successful embryo-biopsy pregnancy and birth in the U.S.; the first clinical trial for gene therapy for Parkinson's disease; the first indication of bone marrow's critical role in tumor growth; and, most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. NewYork-Presbyterian Hospital also comprises NewYork-Presbyterian Hospital/Columbia University Medical Center, NewYork-Presbyterian/Morgan Stanley Children's Hospital, NewYork-Presbyterian Hospital/Westchester Division and NewYork-Presbyterian/The Allen Hospital. NewYork-Presbyterian is the #1 hospital in the New York metropolitan area and is consistently ranked among the best academic medical institutions in the nation, according to U.S.News & World Report. Weill Cornell Medical College is the first U.S. medical college to offer a medical degree overseas and maintains a strong global presence in Austria, Brazil, Haiti, Tanzania, Turkey and Qatar. For more information, visit www.nyp.org and www.med.cornell.edu.
Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Materials Sciences
06.12.2016 | Medical Engineering
06.12.2016 | Power and Electrical Engineering